Study of two targeted drugs for leukemia with certain genetic changes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two medications, ziftomenib and mezigdomide, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It is specifically for patients whose leukemia cells have a particular genetic change, which the drugs are designed to target.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old (16 or older for the first part of the study) and weigh at least 40 kg.
- Your leukemia must have a specific genetic change called KMT2A rearrangement or NPM1 mutation.
- Your leukemia must have returned or not gone away after at least one prior treatment.
- You must be generally well enough to be up and about for at least half of the day (ECOG 0-2).
- Your heart, liver, and kidney function must be within acceptable levels.
- You must be able to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
Hear when a new KMT2A-rearranged trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.